What is Kindbody?
Founded in 2018 and headquartered in New York City, Kindbody operates at the intersection of healthcare and technology. The company provides a comprehensive suite of fertility, gynecology, and wellness services through its modern, tech-enabled clinics. By integrating clinical care with a digital-first patient experience, Kindbody has positioned itself as a disruptive force in the fertility industry, addressing the growing demand for accessible, transparent, and high-quality reproductive health solutions. The company's business model focuses on vertical integration, allowing for greater control over the patient journey and operational efficiency.
How much funding has Kindbody raised?
Kindbody has raised a total of $234M across 5 funding rounds:
Series A
$15M
Series B
$32M
Series C
$62M
Private Equity
$100M
Private Equity
$25M
Series A (2019): $15M, investors not publicly disclosed
Series B (2020): $32M led by GV, Claritas Capital, Perceptive Advisors, Rock Springs Capital, RRE, Freemark Capital, and Goodgrower
Series C (2021): $62M supported by Monashee Investment Management, Theresa Sexton, Eldridge Industries, and Bramalea Partners
Private Equity (2023): $100M featuring Perceptive Advisors
Private Equity (2023): $25M backed by JPMorgan Chase
Key Investors in Kindbody
Perceptive Advisors
Based in New York, this investment firm manages approximately $7 billion in assets and maintains a dedicated focus on funding innovative healthcare and life sciences technologies.
Eldridge Industries
A global holding company that manages a diversified portfolio across sectors including finance, technology, and infrastructure, providing strategic capital to build and scale businesses.
GV
A prominent venture capital firm that invests across multiple stages and sectors, with a specific focus on enterprise solutions, life sciences, and frontier technology innovations.
What's next for Kindbody?
The infusion of capital from recent financing rounds provides Kindbody with the necessary resources to accelerate its national footprint and enhance its proprietary technology platform. As the company transitions through its current lifecycle stage, the focus is expected to shift toward optimizing patient outcomes, scaling clinic operations, and deepening its integration with enterprise-level health benefits providers. By leveraging its recent strategic backing, Kindbody is well-positioned to capitalize on the increasing institutional interest in fertility and women's health, potentially setting the stage for further market consolidation or expansion into adjacent wellness verticals.
See full Kindbody company page
